Tucidinostat

DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options.

Clinical trials evaluating histone deacetylase (HDAC) inhibitors in breast cancer (BRCA) are underway across 24 regions, with the United States and China leading the efforts.

HUYABIO presented Phase 2 data on HBI-8000 combined with nivolumab for advanced melanoma at the SITC Annual Meeting, revealing encouraging efficacy signals.

A Phase II clinical trial evaluated the combination of ASC22, an anti-PD-L1 antibody, and chidamide, a histone deacetylase inhibitor, in HIV-infected adults on ART.